In seven children jaundice resolved by age 1.5 to 6 months (mean 3.5 months) with normal total serum bilirubin concentrations. Three of the seven children died of respiratory failure and malnutrition at ages 3.5, 4, and 19 years respectively. In two of them, hepatomegaly was still present and liver function tests were normal in the two patients tested (table  1) .The other four are alive age 6 to 10 years old. At the latest follow up, hepatosplenomegaly with portal hypertension was present only in the patient with al-antitrypsin deficiency; the liver and the spleen were not palpable in the three others, and abdomen ultrasonography was normal in one. Two patients have been treated with ursodeoxycholic acid for two and five years respectively with biologi-cal improvement in only one of them. All but one of these seven children presented with relapsing episodes of bronchopulmonary infections with chest radiography compatible with cystic fibrosis lesions; two had episodes of hyponatraemic dehydration including one during an episode of heat stroke. Hydrocortisone has been administered daily to the patient with hypopituitarism and at the age of 10 months transection of the pituitary stalk was evidenced by magnetic resonance imaging; growth hormone and partial thyroid stimulating hormone deficiency were demonstrated. Treatment by growth hormone and L-thyroxine was added, and resulted in a progressive ability to thrive. This patient is doing well with satisfactory lung and liver status and with no mental retardation.
Discussion
Although several reports have already described neonatal cholestasis in patients suffering from cystic fibrosis, the patients reported here enabled us to stress various points regarding this association.
Neonatal cholestasis associated with cystic fibrosis is a rare condition. We found 31 children described in English language publications,' 19 and seven more in French journals.""'5 In our series the incidence of cystic fibrosis among causes of neonatal cholestasis was 6/1000. The true incidence may be lower as at least two patients in this series also had another condition known to be associated with neonatal cholestasis. 26 However the presence of mucous material in the lumen of the extrahepatic as well as in intrahepatic bile ducts seen in one patient and already reported is compatible with a bile excretion defect at the origin of cholestasis in these children. 27 Many of the features of cystic fibrosis associated neonatal cholestasis are non-specific or even misleading. In two patients reported here, the permanently acholic stools and firm hepatomegaly were consistent with a clinical diagnosis of biliary atresia. In one of them however, necropsy showed patency of the extrahepatic biliary duct. Two other reports dealing with the same problem conclude differently. Perkins et al consider that a positive sweat chloride test should postpone surgery 1 but Festen et al suggest that intervention is essential because they had histological evidence for biliary atresia in one patient with cystic fibrosis.'7 The liver histology is of little help in most cases because, in our series, only one child displayed the typical mucous plug in the interlobular bile ducts. In most cases liver histology shows features compatible with bile duct obstruction. Finally there were no respiratory symptoms during the early months, although all surviving children presented with respiratory symptoms subsequently.28
We confirm, as has already been shown, 2 9 12 that delay in meconium passage, present in four of these children, is a valuable marker for the diagnosis of cystic fibrosis in children with neonatal cholestasis. Another valuable finding is the presence of normal serum cholesterol concentration, present in seven of the nine children, despite severe cholestatic jaundice. The only child with a high serum cholesterol concentration also had al-antitrypsin deficiency, which may have increased the cholesterol levels. Serum cholesterol concentrations are reported for nine patients described in the literature 6 9 20 22 24 and were normal in seven, in addition to another with raised total serum cholesterol and associated cytomegalovirus hepatitis.
Prognosis of the liver condition in neonates with cystic fibrosis and cholestatic jaundice is varied; it may lead to liver failure after a few months as in patient 4 of our series,22 or it may progress to early cirrhosis as in patient 6, in whom associated al-antitrypsin deficiency may have increased the risk of cirrhosis. In six children of our series, however, there were no evident signs of cirrhosis with a follow up of 3.5 to 19 years. Thus neonatal cholestasis is not necessarily predictive of an early occurrence of cirrhosis. '5 In the 38 cases of neonatal cholestasis associated with cystic fibrosis described in the literature, cirrhosis during infancy has been reported in six cases at ages of 1 month to 1 year, and cirrhosis was seen at necropsy. However, there is no significant follow up for the other children reported, such that it is not possible to estimate the true overall incidence of cirrhosis in children with cystic fibrosis who present with neonatal cholestasis.
As many factors have been proposed as causing neonatal cholestasis in cystic fibrosis, different kinds of treatment, both conservative and aggressive, have been reported in the literature. 6 8 12 17 19 Ursodeoxycholic acid treatment, recommended for patients with meconium ileus, may also benefit patients with neonatal cholestasis due to the same disease.2930
